EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature

Eleonora Paganoni, Paola Sabbadini, Antonio D'Avolio, Jessica Cusato, Giovanna Motta, Letizia Galeasso, Roberto Filippi, Massimo Di Maio, Ilaria Depetris

Cancer Chemotherapy and Pharmacology · 20.05.2026 · 96 (1)

DOI: 10.1007/s00280-026-04903-y ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 20.05.2026. Verfasst von Eleonora Paganoni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Turin, Orbassano, Italy. eleonora.paganoni@unito.it. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, Prostatic Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Androgen deprivation therapy (ADT) is the cornerstone of advanced prostate cancer treatment, aiming to achieve castrate testosterone levels. Luteinizing hormone-releasing hormone (LHRH) agonists are widely used, but intrinsic resistance, although rare, may pose significant therapeutic challenges. CASE PRESENTATION: We report a 75-year-old man with de novo low-volume metastatic prostate cancer who experienced unusual refractoriness to LHRH agonist therapy. Despite correct administration of leuprolide and good treatment adherence, testosterone levels did not drop and instead progressively increased over five months. This occurred concurrently with a marked PSA decline following the addition of the androgen receptor pathway inhibitor (ARPI) apalutamide. Drug-drug interactions, pharmacological interference, and other common causes of treatment resistance were ruled out. Upon switching to the LHRH antagonist degarelix, adequate testosterone suppression was rapidly achieved. DISCUSSION: This case highlights a rare biochemical failure of LHRH agonist therapy, possibly due to primary resistance or inadequate receptor desensitization. The concomitant use of an ARPI masked ADT failure by suppressing PSA despite elevated testosterone. This case emphasizes the still relevant need for periodic testosterone monitoring to ensure effective hormonal suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gonadotropin-Releasing HormoneProstatic NeoplasmsAntineoplastic Agents, HormonalMaleHumansAgedLeuprolideOligopeptidesTreatment FailureTestosteroneProstate-Specific AntigenDrug Resistance, NeoplasmAndrogen AntagonistsThiohydantoins

Stichwörter der Autor:innen

Androgen deprivation therapy failureApalutamideLHRH agonist resistanceMetastatic hormone-sensitive prostate cancerTestosterone escape

Substanzen

Gonadotropin-Releasing HormoneLeuprolideacetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(…apalutamideOligopeptidesAntineoplastic Agents, HormonalTestosteroneProstate-Specific AntigenAndrogen AntagonistsThiohydantoins

Autor:innen und Institutionen

  • Department of Oncology, University of Turin, Orbassano, Italy. eleonora.paganoni@unito.it.
  • Division of Medical Oncology 1U, AOU Città della Salute e della Scienza di Torino, Turin, Italy. eleonora.paganoni@unito.it.
  • Department of Oncology, University of Turin, Orbassano, Italy.
  • Division of Medical Oncology 1U, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
  • Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.

Zitieren

APA

Paganoni, E., Sabbadini, P., D'Avolio, A., Cusato, J., Motta, G., Galeasso, L., Filippi, R., Di Maio, M., & Depetris, I. (2026). Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04903-y

Vancouver

Paganoni E, Sabbadini P, D'Avolio A, Cusato J, Motta G, Galeasso L, et al. Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04903-y

BibTeX
@article{Paganoni2026,
  author = {Paganoni, Eleonora and Sabbadini, Paola and D'Avolio, Antonio and Cusato, Jessica and Motta, Giovanna and Galeasso, Letizia and Filippi, Roberto and Di Maio, Massimo and Depetris, Ilaria},
  title = {Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04903-y}
}
Kostenlos starten →